Hot Pursuit     19-Jun-23
Zydus Lifesciences gets final USFDA nod for Minocycline Hydrochloride tablets
Zydus Lifesciences said that it has received final approval from US Food and Drug Administration (USFDA) for Minocycline Hydrochloride tablets.
The said drug is equivalent to reference listed drug product, Solodyn tablets. Minocycline Hydrochloride is used to treat moderate to severe acne in people 12 years and older. Minocycline belongs to a class of drugs known as tetracycline antibiotics. The product will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad (India).

According to IQVIA MAT April 2023, Minocycline Hydrochloride tablets USP, 55 mg, 65 mg, and 115 mg had annual sales of $0.7 mn in the United States.

As on 31 March 2023, the group has 372 approvals and has so far filed over 442 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company's consolidated net profit (from continuing operations) tumbled 27.55% to Rs 298.8 crore despite of 31.66% jump in total revenue from operations to Rs 5,010.6 crore in Q4 FY23 over Q4 FY22.

The scrip rose 0.86% to Rs 555 on the BSE.

Previous News
  Zydus receives USFDA tentative approval for Azilsartan Medoxomil and Chlorthalidone Tablets
 ( Corporate News - 14-Jun-24   13:42 )
  Board of Zydus Lifesciences recommends Final Dividend
 ( Corporate News - 17-May-24   16:18 )
  Zydus Lifesciences appoints director
 ( Corporate News - 17-May-24   15:47 )
  Zydus Life gets tentative USFDA nod for hypertension drugs
 ( Hot Pursuit - 14-Jun-24   12:34 )
  Zydus Lifesciences launches cancer drug - IBYRA in India
 ( Corporate News - 13-Mar-24   16:31 )
  Zydus Lifesciences to hold AGM
 ( Corporate News - 17-May-24   17:45 )
  Zydus Lifesciences Ltd gains for third straight session
 ( Hot Pursuit - 02-Jan-24   13:05 )
  Zydus Life arm gets IT demand notice of Rs 285 cr
 ( Hot Pursuit - 27-Dec-23   11:06 )
  Zydus Lifesciences consolidated net profit rises 26.76% in the December 2023 quarter
 ( Results - Announcements 09-Feb-24   14:29 )
  Zydus Life gets US FDA nod for anti-cancer medication Cyclophosphamide
 ( Hot Pursuit - 14-Dec-23   14:31 )
  Zydus receives WHO approval for the name ‘Usnoflast' for ZYIL1
 ( Corporate News - 01-Apr-24   20:34 )
Other Stories
  RVNL gains on emerging as L-1 bidder for Rs 133-cr railway project
  03-Jul-24   15:38
  Cholamandalam Financial Holdings Ltd leads losers in 'A' group
  03-Jul-24   15:00
  Sakuma Exports Ltd leads losers in 'B' group
  03-Jul-24   14:45
  NTPC power generation climbs 9.5% YoY in Q1
  03-Jul-24   14:41
  Volumes soar at MMTC Ltd counter
  03-Jul-24   14:30
  Oil and Gas shares fall
  03-Jul-24   14:00
  Real Estate stocks edge lower
  03-Jul-24   14:00
  Energy stocks edge lower
  03-Jul-24   14:00
  Sundaram-Clayton gains after board OKs to raise funds upto Rs 400 cr
  03-Jul-24   13:38
  JSW Infra's subsidiary concession agreement V.O. Chidambaranar Port Authority
  03-Jul-24   13:34
Back Top